Antiplatelet Market Analysis, Share, Growth & Forecast 2031

Report Description

The global antiplatelet market size is projected to register a substantial CAGR during the forecast period, 2021-2028 attributed to the increasing number of chronic diseases that result in thrombosis and the proliferation of anticoagulant drugs. Furthermore, the market growth can be accredited to the availability of generic drugs that are present in the market at low cost.

Get Free Sample Report

The phenomenon when blood clots in the blood vessels and remains stuck in the vessel is known as thrombus. In order to reduce these blood clots, antithrombotic agents are used, which can prevent or continue treatment of blood clots. Different blood clotting is affected by different antithrombotics such as thrombolytic drugs, anticoagulants, and antiplatelet drugs. The main application of antithrombotics is to treat the abnormal flow of blood in the human body. Some of the major factors that cause thrombus are smoking, obesity, pregnancy, damage in the blood vessels, inactivity, and genetic & medical conditions.

Individuals who are at high risk of getting a heart attack are given antithrombotic as most of the heart attacks are caused when blood clots happened in the arteries, which are connected to the heart muscles. When people are provided with antiplatelet agents, their risk of having heart attacks or strokes can be avoided. The formation of thrombotic can be prohibited along with a decrease in the platelet aggregation by the usage of antiplatelet drugs, which is a member of a pharmaceutical class. For the prevention of cardiovascular diseases, these agents are widely used. For the treatment & prevention of ischemic events such as stroke, peripheral occlusion, acute coronary syndrome, venous thromboembolism, and myocardial infarction various antithrombotics are used.

Market Trends, Drivers, Restraints, and Opportunities

• Wide increase in the incidence of hereditary and cardiac diseases is anticipated to fuel the growth of the market during the forecast period.
• Increasing demand for oral novel anticoagulants along with the increasing geriatric population is expected to propel the growth of the market over the forecast period.
• Lack of availability of alternatives for antithrombotic drugs and availability of strong drug pipelines are estimated to boost the market growth in the coming years.
• High cost of novel drugs and issues concerning side effects caused by antithrombotic drugs along with rigid & strict regulatory policies are some key challenges that can restrain the market growth.
• Pharmaceutical advancements and the development & launch of new products are some major factors that are projected to create profitable opportunities for the market growth.

Scope of the Report

The report on the global antiplatelet market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Market Segment Insights

Antiplatelet drugs segment is expected to grow at a significant rate

On the basis of drugs, the global antiplatelet market is divided into thrombolytic drugs, anticoagulants, and antiplatelet drugs. The antiplatelet drugs segment is expected to grow at a significant rate during the projected period owing to its wide usage by professionals for long-term prevention. The migration of platelets is reduced or limited by the usage of antiplatelet drugs as they can restrain the process of damage of blood vessel endothelium. The coagulation of blood is prevented by a class of drugs known as anticoagulants. These are naturally present in blood-sucking insects including leeches. Anticoagulants are also used in medical equipment that includes bags for blood transfusion, test tubes, and equipment for renal dialysis. The clots forms in the vessels are dissolved by the usage of thrombolytic drugs and this process is known as thrombolysis. Some of the antiplatelet drugs, anticoagulant drugs, and thrombolytic drugs that are commonly used are Eptifibatide, Abciximab, Glycoprotein IIb/IIIa inhibitors, Certoparin, Bemiparin, Glycosaminoglycans, Factor Xa inhibitor, and r-tPA.

Get Free Sample Report

Asia Pacific is estimated to expand at a considerable pace

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a significant share of the market in 2019 and is projected to exhibit a high CAGR during the forecast period owing to the presence of well-established healthcare infrastructure, increasing incidence of cardiac disorders, and favorable reimbursement policies in the region. On the other hand, the market of Asia Pacific is estimated to expand at a considerable growth pace in the coming years attributed to the strong availability of the generic drugs and the presence of a high number of cardiac diseases patients in the region.

Get Free Sample Report